Simvastatin-ezetimibe-induced	simvastatin-ezetimibe-induced	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
necessitating	necessitating	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
.	.	O	O	O	O

Abstract	abstract	O	O	O	O
Serum	serum	O	O	O	O
aminotransferase	aminotransferase	O	O	O	O
elevations	elevations	O	O	O	O
are	are	O	O	O	O
a	a	O	O	O	O
commonly	commonly	O	O	O	O
known	known	O	O	O	O
adverse	adverse	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
3-hydroxy-3-methylglutaryl	3-hydroxy-3-methylglutaryl	O	O	O	O
coenzyme	coenzyme	CHEMICALS	O	OTHERS	I
A	a	CHEMICALS	O	OTHERS	I
reductase	reductase	O	O	O	O
inhibitor	inhibitor	O	O	O	O
(	(	O	O	O	O
statin	statin	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
hepatotoxic	hepatotoxic	O	DISEASE	OTHERS	I
events	events	O	O	O	O
have	have	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
widely	widely	O	O	O	O
published	published	O	O	O	O
with	with	O	O	O	O
ezetimibe	ezetimibe	O	O	OTHERS	I
or	or	O	O	O	O
the	the	O	O	O	O
combination	combination	O	O	O	O
agent	agent	O	O	O	O
simvastatin-ezetimibe	simvastatin-ezetimibe	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
a	a	O	O	O	O
70-year-old	70-year-old	O	O	O	O
Hispanic	hispanic	O	O	O	O
woman	woman	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
fulminant	fulminant	O	DISEASE	OTHERS	I
hepatic	hepatic	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
necessitating	necessitating	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
10	10	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
conversion	conversion	O	O	O	O
from	from	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
40	40	O	O	O	O
mg/day	mg/day	O	O	O	O
to	to	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
10	10	O	O	O	O
mg-ezetimibe	mg-ezetimibe	O	O	O	O
40	40	O	O	O	O
mg/day	mg/day	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
lipid	lipid	O	O	O	O
panel	panel	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
maintained	maintained	O	O	O	O
with	with	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
18	18	O	O	O	O
months	months	O	O	O	O
before	before	O	O	O	O
the	the	O	O	O	O
conversion	conversion	O	O	O	O
without	without	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
routine	routine	O	O	O	O
laboratory	laboratory	O	O	O	O
work-up	work-up	O	O	O	O
10	10	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
conversion	conversion	O	O	O	O
revealed	revealed	O	O	O	O
elevated	elevated	O	O	O	O
serum	serum	O	O	O	O
aminotransferase	aminotransferase	O	O	O	O
levels	levels	O	O	O	O
.	.	O	O	O	O

Simvastatinezetimibe	simvastatinezetimibe	O	O	OTHERS	I
and	and	O	O	O	O
escitalopram	escitalopram	O	O	OTHERS	I
(	(	O	O	O	O
which	which	O	O	O	O
she	she	O	O	O	O
was	was	O	O	O	O
taking	taking	O	O	O	O
for	for	O	O	O	O
depression	depression	O	DISEASE	OTHERS	I
)	)	O	O	O	O
were	were	O	O	O	O
discontinued	discontinued	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
other	other	O	O	O	O
potential	potential	O	O	O	O
causes	causes	O	O	O	O
of	of	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
were	were	O	O	O	O
excluded	excluded	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
repeat	repeat	O	O	O	O
work-up	work-up	O	O	O	O
revealed	revealed	O	O	O	O
further	further	O	O	O	O
elevations	elevations	O	O	O	O
in	in	O	O	O	O
aminotransferase	aminotransferase	O	O	O	O
levels	levels	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
liver	liver	O	O	O	O
biopsy	biopsy	O	O	O	O
revealed	revealed	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
moderate-to-severe	moderate-to-severe	O	O	O	O
drug	drug	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

She	she	O	O	O	O
underwent	underwent	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
with	with	O	O	O	O
an	an	O	O	O	O
uneventful	uneventful	O	O	O	O
postoperative	postoperative	O	O	O	O
course	course	O	O	O	O
.	.	O	O	O	O

Her	her	O	O	O	O
aminotransferase	aminotransferase	O	O	O	O
levels	levels	O	O	O	O
returned	returned	O	O	O	O
to	to	O	O	O	O
normal	normal	O	O	O	O
by	by	O	O	O	O
postoperative	postoperative	O	O	O	O
day	day	O	O	O	O
23	23	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
her	her	O	O	O	O
2-year	2-year	O	O	O	O
follow-up	follow-up	O	O	O	O
showed	showed	O	O	O	O
no	no	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
.	.	O	O	O	O

Ezetimibe	ezetimibe	O	O	OTHERS	I
undergoes	undergoes	O	O	O	O
extensive	extensive	O	O	O	O
glucuronidation	glucuronidation	O	O	O	O
by	by	O	O	O	O
uridine	uridine	CHEMICALS	O	OTHERS	I
diphosphate	diphosphate	CHEMICALS	O	OTHERS	I
glucoronosyltransferases	glucoronosyltransferases	O	O	O	O
(	(	O	O	O	O
UGT	ugt	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
intestine	intestine	O	O	O	O
and	and	O	O	O	O
liver	liver	O	O	O	O
and	and	O	O	O	O
may	may	O	O	O	O
have	have	O	O	O	O
inhibited	inhibited	O	O	O	O
the	the	O	O	O	O
glucuronidation	glucuronidation	O	O	O	O
of	of	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
hydroxy	hydroxy	O	O	OTHERS	I
acid	acid	O	O	OTHERS	I
,	,	O	O	O	O
resulting	resulting	O	O	O	O
in	in	O	O	O	O
increased	increased	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
and	and	O	O	O	O
subsequent	subsequent	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

To	to	O	O	O	O
our	our	O	O	O	O
knowledge	knowledge	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
is	is	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
case	case	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
simvastatin-ezetimibe-induced	simvastatin-ezetimibe-induced	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
that	that	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
liver	liver	O	O	O	O
transplantation	transplantation	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
postulate	postulate	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
mechanism	mechanism	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
simvastatinezetimibe-induced	simvastatinezetimibe-induced	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
increased	increased	O	O	O	O
simvastatin	simvastatin	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
by	by	O	O	O	O
ezetimibe	ezetimibe	O	O	OTHERS	I
inhibition	inhibition	O	O	O	O
of	of	O	O	O	O
UGT	ugt	O	O	O	O
enzymes	enzymes	O	O	O	O
.	.	O	O	O	O

Clinicians	clinicians	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
aware	aware	O	O	O	O
of	of	O	O	O	O
potential	potential	O	O	O	O
hepatotoxicity	hepatotoxicity	O	DISEASE	OTHERS	I
with	with	O	O	O	O
simvastatin-ezetimibe	simvastatin-ezetimibe	O	O	O	O
especially	especially	O	O	O	O
in	in	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
should	should	O	O	O	O
carefully	carefully	O	O	O	O
monitor	monitor	O	O	O	O
serum	serum	O	O	O	O
aminotransferase	aminotransferase	O	O	O	O
levels	levels	O	O	O	O
when	when	O	O	O	O
starting	starting	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
titrating	titrating	O	O	O	O
the	the	O	O	O	O
dosage	dosage	O	O	O	O
.	.	O	O	O	O

